Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Chris Lindsay, a BHF CRE funded DPhil student jointly supervised by Angela Russell and Rebecca Sitsapesan, has been awarded the poster prize at the British Pharmacological Society meeting in Edinburgh - Pharmacology Futures. The conference focused on exploring the technologies that will drive drug development over the next 10 to 15 years, with speakers sharing their visions of the future. Chris presented his work on using electrophysiology to elucidate the mechanism of statin side effects, towards the development of next generation HMG-CoA inhibitors.

Similar stories

EMA approval of IntraBio’s Aqneursa marks a major milestone for the Department of Pharmacology, with further Phase 3 success in Ataxia Telangiectasia

On 21 January, the European Medicines Agency (EMA) approved Aqneursa, a new treatment for Niemann-Pick Disease Type C (NPC) in adults and children, marking a major milestone for research originating in the Department of Pharmacology. Aqneursa already received US FDA approval (September 2024), enabling patient access on both sides of the Atlantic.